As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...
Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...
'Mad Money' host Jim Cramer weighs in on stock including: Viper Energy, Nextracker, Trump Media, Eli Lilly, and Dutch Bros.
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...
Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback